The global pharmaceutical industry is witnessing a surge in strategic partnerships and acquisitions as companies strengthen their pipelines and invest in next-generation therapeutics. According to a roundup published on February 25, 2026, major deals involving Novo Nordisk and GSK highlight growing focus on biologics, drug delivery innovation, and cardiopulmonary treatments.
Novo Nordisk Partners with Vivtex for Oral Biologics
On February 25, 2026, Novo Nordisk entered into a strategic partnership with Vivtex Corporation to develop next-generation oral biologic medicines targeting obesity, diabetes, and related metabolic conditions.
The agreement includes licensing Vivtex’s oral drug-delivery technologies, with potential milestone payments and royalties totalling up to $2.1 billion.
This collaboration aims to overcome one of the key challenges in biologics—oral delivery—by enabling traditionally injectable therapies to be administered in pill form, significantly improving patient convenience and adherence.
GSK to Acquire 35Pharma to Strengthen Pipeline
In a parallel development on February 25, 2026, GSK announced an agreement to acquire Canada-based biopharmaceutical company 35Pharma Inc. for $950 million in cash.
The acquisition is focused on expanding GSK’s pipeline in pulmonary hypertension and cardiopulmonary diseases. The deal includes 35Pharma’s lead asset, HS235, a novel investigational therapy targeting the activin receptor signalling pathway.
This molecule has shown potential as a differentiated treatment option for pulmonary hypertension, a condition with limited therapeutic alternatives and high unmet medical need.
Strategic Focus on Next-Generation Therapeutics
The deals announced on February 25, 2026, reflect a broader industry trend toward investing in advanced therapeutic platforms, including:
- Oral biologics and innovative drug delivery systems
- Protein-based therapeutics and biologics
- Targeted treatments for chronic and high-burden diseases
Pharmaceutical companies are increasingly pursuing partnerships and acquisitions to access specialized technologies, accelerate drug development, and maintain competitive advantage in rapidly evolving therapeutic areas.
Strengthening Global Pharma Pipelines
Both transactions highlight the importance of pipeline expansion and diversification. Novo Nordisk is focusing on metabolic diseases and obesity, while GSK is strengthening its cardiopulmonary portfolio through targeted acquisitions.
These strategies are aligned with the industry’s shift toward high-value, innovative therapies that address unmet clinical needs and deliver long-term growth opportunities.
Outlook
The developments reported on February 25, 2026, underscore the increasing role of strategic collaborations and acquisitions in shaping the future of the pharmaceutical industry. As competition intensifies and demand for advanced therapies grows, companies are expected to continue investing in innovative platforms and specialized capabilities.
These deals position both Novo Nordisk and GSK to enhance their global market presence while advancing the development of next-generation treatments across key therapeutic areas.
